ZA200600419B - Indol-6 sulfonamide derivatives, their preparation and their use as 5-HT-6 modulators - Google Patents
Indol-6 sulfonamide derivatives, their preparation and their use as 5-HT-6 modulators Download PDFInfo
- Publication number
- ZA200600419B ZA200600419B ZA200600419A ZA200600419A ZA200600419B ZA 200600419 B ZA200600419 B ZA 200600419B ZA 200600419 A ZA200600419 A ZA 200600419A ZA 200600419 A ZA200600419 A ZA 200600419A ZA 200600419 B ZA200600419 B ZA 200600419B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound according
- optionally
- mono
- medicament
- prophylaxis
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title description 3
- AFJYOUBTIAOUQI-UHFFFAOYSA-N 1h-indole-6-sulfonamide Chemical class NS(=O)(=O)C1=CC=C2C=CNC2=C1 AFJYOUBTIAOUQI-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 100
- -1 sulfonamide compound Chemical class 0.000 claims description 95
- 229910052739 hydrogen Inorganic materials 0.000 claims description 73
- 239000001257 hydrogen Substances 0.000 claims description 73
- 239000003814 drug Substances 0.000 claims description 68
- 238000011282 treatment Methods 0.000 claims description 67
- 238000011321 prophylaxis Methods 0.000 claims description 66
- 238000004519 manufacturing process Methods 0.000 claims description 58
- 125000005842 heteroatom Chemical group 0.000 claims description 50
- 229920006395 saturated elastomer Polymers 0.000 claims description 49
- 150000003254 radicals Chemical class 0.000 claims description 45
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 35
- 125000000217 alkyl group Chemical group 0.000 claims description 31
- 125000002950 monocyclic group Chemical group 0.000 claims description 29
- 208000035475 disorder Diseases 0.000 claims description 26
- 150000002431 hydrogen Chemical class 0.000 claims description 25
- 229940124530 sulfonamide Drugs 0.000 claims description 21
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 15
- 208000008589 Obesity Diseases 0.000 claims description 15
- 125000004122 cyclic group Chemical group 0.000 claims description 15
- 235000020824 obesity Nutrition 0.000 claims description 15
- 125000003367 polycyclic group Chemical class 0.000 claims description 15
- 208000024827 Alzheimer disease Diseases 0.000 claims description 14
- 206010012601 diabetes mellitus Diseases 0.000 claims description 14
- 150000003456 sulfonamides Chemical class 0.000 claims description 14
- 125000002619 bicyclic group Chemical group 0.000 claims description 13
- 229910052801 chlorine Inorganic materials 0.000 claims description 13
- 239000000460 chlorine Substances 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 11
- 125000004450 alkenylene group Chemical group 0.000 claims description 11
- 125000004419 alkynylene group Chemical group 0.000 claims description 11
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 10
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 10
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 10
- 229910052794 bromium Inorganic materials 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 239000012453 solvate Substances 0.000 claims description 9
- 208000019901 Anxiety disease Diseases 0.000 claims description 8
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 8
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 8
- 206010020651 Hyperkinesia Diseases 0.000 claims description 8
- 208000000269 Hyperkinesis Diseases 0.000 claims description 8
- 208000026139 Memory disease Diseases 0.000 claims description 8
- 230000036506 anxiety Effects 0.000 claims description 8
- 210000003169 central nervous system Anatomy 0.000 claims description 8
- 230000001149 cognitive effect Effects 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 239000011737 fluorine Substances 0.000 claims description 8
- 230000037406 food intake Effects 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 201000000980 schizophrenia Diseases 0.000 claims description 8
- 208000032841 Bulimia Diseases 0.000 claims description 7
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 7
- 206010006895 Cachexia Diseases 0.000 claims description 7
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical compound F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 claims description 7
- 208000023105 Huntington disease Diseases 0.000 claims description 7
- 208000018737 Parkinson disease Diseases 0.000 claims description 7
- 208000028017 Psychotic disease Diseases 0.000 claims description 7
- 206010039966 Senile dementia Diseases 0.000 claims description 7
- 125000004414 alkyl thio group Chemical group 0.000 claims description 7
- 208000022531 anorexia Diseases 0.000 claims description 7
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 7
- 230000037396 body weight Effects 0.000 claims description 7
- 230000037410 cognitive enhancement Effects 0.000 claims description 7
- 206010061428 decreased appetite Diseases 0.000 claims description 7
- 235000012631 food intake Nutrition 0.000 claims description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 7
- 238000012423 maintenance Methods 0.000 claims description 7
- 201000006417 multiple sclerosis Diseases 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 230000003893 regulation of appetite Effects 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 7
- 208000020925 Bipolar disease Diseases 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 230000033228 biological regulation Effects 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- JEVCWSUVFOYBFI-UHFFFAOYSA-N cyanyl Chemical compound N#[C] JEVCWSUVFOYBFI-UHFFFAOYSA-N 0.000 claims description 6
- 125000000623 heterocyclic group Chemical class 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 208000019906 panic disease Diseases 0.000 claims description 5
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- HFFXLYHRNRKAPM-UHFFFAOYSA-N 2,4,5-trichloro-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C(=CC(Cl)=C(Cl)C=2)Cl)=N1 HFFXLYHRNRKAPM-UHFFFAOYSA-N 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 2
- 230000007278 cognition impairment Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- OTBFUMSMIVYLAK-UHFFFAOYSA-N 1,3-thiazole-5-sulfonamide Chemical compound NS(=O)(=O)C1=CN=CS1 OTBFUMSMIVYLAK-UHFFFAOYSA-N 0.000 claims 1
- MIMYTSWNVBMNRH-UHFFFAOYSA-N 1h-indol-6-amine Chemical compound NC1=CC=C2C=CNC2=C1 MIMYTSWNVBMNRH-UHFFFAOYSA-N 0.000 claims 1
- PHDLHKXIMTZUKZ-UHFFFAOYSA-N 3,5-dichloro-n-[1-[2-(dimethylamino)ethyl]indol-6-yl]benzenesulfonamide Chemical compound C1=C2N(CCN(C)C)C=CC2=CC=C1NS(=O)(=O)C1=CC(Cl)=CC(Cl)=C1 PHDLHKXIMTZUKZ-UHFFFAOYSA-N 0.000 claims 1
- YJKGUHLFARNGHG-UHFFFAOYSA-N 4-phenoxy-n-[1-(2-pyrrolidin-1-ylethyl)indol-6-yl]benzenesulfonamide Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1S(=O)(=O)NC(C=C12)=CC=C1C=CN2CCN1CCCC1 YJKGUHLFARNGHG-UHFFFAOYSA-N 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000008050 dialkyl sulfates Chemical class 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- YBMWPCIPYFXGAM-UHFFFAOYSA-N n-[1-[2-(dimethylamino)ethyl]indol-6-yl]-2-naphthalen-1-ylethanesulfonamide Chemical compound C1=CC=C2C(CCS(=O)(=O)NC3=CC=C4C=CN(C4=C3)CCN(C)C)=CC=CC2=C1 YBMWPCIPYFXGAM-UHFFFAOYSA-N 0.000 claims 1
- AUIIXCCJDYHWEM-UHFFFAOYSA-N n-[1-[2-(dimethylamino)ethyl]indol-6-yl]-4-phenoxybenzenesulfonamide Chemical compound C1=C2N(CCN(C)C)C=CC2=CC=C1NS(=O)(=O)C(C=C1)=CC=C1OC1=CC=CC=C1 AUIIXCCJDYHWEM-UHFFFAOYSA-N 0.000 claims 1
- MMVUKQDPMLJEFQ-UHFFFAOYSA-N n-[1-[2-(dimethylamino)ethyl]indol-6-yl]naphthalene-1-sulfonamide Chemical compound C1=CC=C2C(S(=O)(=O)NC3=CC=C4C=CN(C4=C3)CCN(C)C)=CC=CC2=C1 MMVUKQDPMLJEFQ-UHFFFAOYSA-N 0.000 claims 1
- GLMWOXAKQHRWJX-UHFFFAOYSA-N n-[1-[2-(dimethylamino)ethyl]indol-6-yl]naphthalene-2-sulfonamide Chemical compound C1=CC=CC2=CC(S(=O)(=O)NC3=CC=C4C=CN(C4=C3)CCN(C)C)=CC=C21 GLMWOXAKQHRWJX-UHFFFAOYSA-N 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 241000282412 Homo Species 0.000 description 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 4
- 229920001774 Perfluoroether Polymers 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 4
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 3
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000005864 Sulphur Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- AQYSYJUIMQTRMV-UHFFFAOYSA-N hypofluorous acid Chemical compound FO AQYSYJUIMQTRMV-UHFFFAOYSA-N 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 108091005478 5-HT1 receptors Proteins 0.000 description 1
- 102000035038 5-HT1 receptors Human genes 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000001459 mortal effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000003523 serotonin 4 antagonist Substances 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200301810A ES2222832B1 (es) | 2003-07-30 | 2003-07-30 | Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200600419B true ZA200600419B (en) | 2007-03-28 |
Family
ID=34130544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200600419A ZA200600419B (en) | 2003-07-30 | 2004-07-29 | Indol-6 sulfonamide derivatives, their preparation and their use as 5-HT-6 modulators |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7462640B2 (ko) |
| EP (1) | EP1660077B1 (ko) |
| JP (1) | JP2007500164A (ko) |
| KR (1) | KR20060123699A (ko) |
| CN (1) | CN100563650C (ko) |
| AR (1) | AR045155A1 (ko) |
| AT (1) | ATE432701T1 (ko) |
| AU (1) | AU2004262484A1 (ko) |
| BR (1) | BRPI0413112A (ko) |
| CA (1) | CA2533970A1 (ko) |
| DE (1) | DE602004021394D1 (ko) |
| ES (2) | ES2222832B1 (ko) |
| IL (1) | IL172894A0 (ko) |
| MX (1) | MXPA06001141A (ko) |
| NO (1) | NO20060682L (ko) |
| NZ (1) | NZ545301A (ko) |
| PE (1) | PE20050280A1 (ko) |
| PT (1) | PT1660077E (ko) |
| RU (1) | RU2006105777A (ko) |
| TW (1) | TW200509907A (ko) |
| WO (1) | WO2005013976A1 (ko) |
| ZA (1) | ZA200600419B (ko) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2222832B1 (es) | 2003-07-30 | 2006-02-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| WO2006019831A1 (en) | 2004-07-14 | 2006-02-23 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
| ES2246721B1 (es) * | 2004-08-10 | 2007-03-16 | Laboratorios Del Dr. Esteve, S.A. | Compuestos indolicos sustituidos, su preparacion y su uso como medicamentos. |
| EP1632491A1 (en) * | 2004-08-30 | 2006-03-08 | Laboratorios Del Dr. Esteve, S.A. | Substituted indole compounds and their use as 5-HT6 receptor modulators |
| US7803828B2 (en) * | 2005-08-25 | 2010-09-28 | Schering-Plough Corporation | Functionally selective alpha2C adrenoreceptor agonists |
| EA014470B1 (ru) * | 2006-01-24 | 2010-12-30 | Эли Лилли Энд Компани | Индолсульфонамидные модуляторы рецепторов прогестерона |
| EP1953153A1 (en) * | 2007-01-31 | 2008-08-06 | Laboratorios del Dr. Esteve S.A. | Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders |
| DE102007007751A1 (de) * | 2007-02-16 | 2008-08-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE102007012284A1 (de) * | 2007-03-16 | 2008-09-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| EP2018861A1 (en) * | 2007-07-26 | 2009-01-28 | Laboratorios del Dr. Esteve S.A. | 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain |
| DE102007035334A1 (de) | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE102007035333A1 (de) | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| ATE495737T1 (de) | 2007-08-01 | 2011-02-15 | Esteve Labor Dr | Kombination von mindestens zwei 5-ht6-liganden |
| DE102007042154A1 (de) | 2007-09-05 | 2009-03-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Arylsulfonylaminomethyphosphonsäure-Derivate, deren Herstellung und deren Verwendung als Arzneimittel |
| EP2053052A1 (en) | 2007-10-23 | 2009-04-29 | Laboratorios del Dr. Esteve S.A. | Process for the preparation of 6-substituted imidazo[2,1-b]thiazole-5-sulfonyl halide |
| EP2116547A1 (en) * | 2008-05-09 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | Substituted N-imidazo(2, 1-b) thiazole-5-sulfonamide derivatives as 5-TH6 ligands |
| PL2300489T3 (pl) | 2008-06-06 | 2016-11-30 | Sposoby wytwarzania 17-alkinylo-7-hydroksysteroidów i związków pokrewnych | |
| ITMC20080120A1 (it) * | 2008-06-20 | 2009-12-21 | Nazario Luzi | Sistema di ripresa video in particolare per la pesca. |
| EP2149573A1 (en) * | 2008-08-01 | 2010-02-03 | Laboratorios Del. Dr. Esteve, S.A. | Substituted indole sulfonamide compounds their preparation and use as medicaments |
| US20190336585A1 (en) * | 2018-05-03 | 2019-11-07 | John Lawrence Mee | Method for sustainable human cognitive enhancement |
| US20190390193A1 (en) * | 2018-06-23 | 2019-12-26 | John Lawrence Mee | Reversible method for sustainable human cognitive enhancement |
| JP2022508648A (ja) | 2018-10-05 | 2022-01-19 | アンナプルナ バイオ インコーポレイテッド | Ａｐｊ受容体活性に関連する状態を処置するための化合物および組成物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3472870A (en) * | 1966-08-29 | 1969-10-14 | Mead Johnson & Co | Sulfonamidotryptamines |
| WO1995032967A1 (en) | 1994-05-28 | 1995-12-07 | Smithkline Beecham Plc | Amide derivatives having 5ht1d-antagonist activity |
| AU702322B2 (en) | 1995-03-20 | 1999-02-18 | Eli Lilly And Company | 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists |
| DE19625184B4 (de) * | 1996-06-24 | 2005-06-30 | Wabag Wassertechnik Gmbh | Verfahren zur Aufbereitung von Prozeßwasser aus einer Flaschenreinigungsmaschine |
| US5939451A (en) | 1996-06-28 | 1999-08-17 | Hoffmann-La Roche Inc. | Use of sulfonamides |
| DE19753522A1 (de) * | 1997-12-03 | 1999-06-10 | Boehringer Ingelheim Pharma | Substituierte Indole, ihre Herstellung und ihre Verwendung als Arzneimittel |
| GB9926302D0 (en) | 1999-11-05 | 2000-01-12 | Smithkline Beecham Plc | Novel compounds |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| BR0206595A (pt) | 2001-01-30 | 2004-07-13 | Lilly Co Eli | Composto, composição farmacêutica, e uso de um composto |
| ES2187300B1 (es) | 2001-11-14 | 2004-06-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos. |
| ATE407671T1 (de) | 2003-05-09 | 2008-09-15 | Esteve Labor Dr | Verwendung von sulfonamid-derivate zur herstellung eines medikaments für die vorbeugung oder behandlung von essstörungen |
| US20050191124A1 (en) * | 2003-06-02 | 2005-09-01 | Yoshitaka Watanabe | Container connecting metal fixture |
| ES2222832B1 (es) | 2003-07-30 | 2006-02-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
-
2003
- 2003-07-30 ES ES200301810A patent/ES2222832B1/es not_active Expired - Fee Related
-
2004
- 2004-07-29 EP EP04741319A patent/EP1660077B1/en not_active Expired - Lifetime
- 2004-07-29 WO PCT/EP2004/008510 patent/WO2005013976A1/en active Application Filing
- 2004-07-29 CN CNB2004800222711A patent/CN100563650C/zh not_active Expired - Fee Related
- 2004-07-29 US US10/566,101 patent/US7462640B2/en not_active Expired - Fee Related
- 2004-07-29 NZ NZ545301A patent/NZ545301A/en unknown
- 2004-07-29 AT AT04741319T patent/ATE432701T1/de not_active IP Right Cessation
- 2004-07-29 ZA ZA200600419A patent/ZA200600419B/en unknown
- 2004-07-29 TW TW093122667A patent/TW200509907A/zh unknown
- 2004-07-29 CA CA002533970A patent/CA2533970A1/en not_active Abandoned
- 2004-07-29 JP JP2006521528A patent/JP2007500164A/ja active Pending
- 2004-07-29 AR ARP040102697A patent/AR045155A1/es unknown
- 2004-07-29 RU RU2006105777/04A patent/RU2006105777A/ru unknown
- 2004-07-29 DE DE602004021394T patent/DE602004021394D1/de not_active Expired - Lifetime
- 2004-07-29 MX MXPA06001141A patent/MXPA06001141A/es active IP Right Grant
- 2004-07-29 PT PT04741319T patent/PT1660077E/pt unknown
- 2004-07-29 ES ES04741319T patent/ES2327845T3/es not_active Expired - Lifetime
- 2004-07-29 BR BRPI0413112-6A patent/BRPI0413112A/pt not_active IP Right Cessation
- 2004-07-29 AU AU2004262484A patent/AU2004262484A1/en not_active Abandoned
- 2004-07-29 KR KR1020067001738A patent/KR20060123699A/ko not_active Application Discontinuation
- 2004-08-02 PE PE2004000735A patent/PE20050280A1/es not_active Application Discontinuation
-
2005
- 2005-12-29 IL IL172894A patent/IL172894A0/en unknown
-
2006
- 2006-02-10 NO NO20060682A patent/NO20060682L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL172894A0 (en) | 2006-06-11 |
| WO2005013976A1 (en) | 2005-02-17 |
| US7462640B2 (en) | 2008-12-09 |
| EP1660077B1 (en) | 2009-06-03 |
| BRPI0413112A (pt) | 2006-10-03 |
| ES2327845T3 (es) | 2009-11-04 |
| KR20060123699A (ko) | 2006-12-04 |
| EP1660077A1 (en) | 2006-05-31 |
| ATE432701T1 (de) | 2009-06-15 |
| CN1832738A (zh) | 2006-09-13 |
| CN100563650C (zh) | 2009-12-02 |
| PE20050280A1 (es) | 2005-06-12 |
| TW200509907A (en) | 2005-03-16 |
| ES2222832A1 (es) | 2005-02-01 |
| MXPA06001141A (es) | 2006-04-24 |
| JP2007500164A (ja) | 2007-01-11 |
| CA2533970A1 (en) | 2005-02-17 |
| AU2004262484A1 (en) | 2005-02-17 |
| RU2006105777A (ru) | 2007-09-20 |
| ES2222832B1 (es) | 2006-02-16 |
| AR045155A1 (es) | 2005-10-19 |
| PT1660077E (pt) | 2009-09-03 |
| NZ545301A (en) | 2008-05-30 |
| US20070043041A1 (en) | 2007-02-22 |
| NO20060682L (no) | 2006-02-10 |
| DE602004021394D1 (de) | 2009-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200600419B (en) | Indol-6 sulfonamide derivatives, their preparation and their use as 5-HT-6 modulators | |
| EP1648443B1 (en) | 1-sulfonylindole derivatives, their preparation and their use as 5-ht6 ligands | |
| HRP20040429A2 (en) | Sulphonamide derivatives, the preparation thereof and the application of same as medicaments | |
| RU2006105779A (ru) | Индол-5-ильные сульфонамидные производные, их получение и их применение в качестве модуляторов 5-нт-6 | |
| JP2007500166A (ja) | インドール−４スルホンアミド誘導体、それらの調製および５−ｈｔ−６調節因子としてのそれらの使用 | |
| ZA200600418B (en) | Indol-7 sulfonamide derivatives, their preparation and their use as 5-HT-6 modulators | |
| JP2009545555A (ja) | 置換インダニルスルホンアミド化合物、それらの調製、および薬剤としての使用 | |
| EP2297166B1 (en) | Substituted n-imidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-ht6 ligands | |
| EP2116546A1 (en) | Substituted N-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-HT6 ligands |